While the evidence is strong and it is listed as an option by NCCN and ESMO, the absolute clinical benefit in addition to chemotherapy is modest.42-45 NICE does not recommend anti-VEGF therapy as cost effective for treatment of patients with late-stage CRC.20 See the Cost Implications section regarding cost effectiveness of treatments in selected resource-constrained countries. Here, VEGFA is linked to colorectal carcinoma.